Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer
Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer
复制标题
DOI：
10.21873/invivo.12718
复制
发表时间：
2022-01-01
期刊：
影响因子：
2.3
通讯作者：
Ohtsuka, Takao
中科院分区：
文献类型：
--
作者：
Arigami, Takaaki;Matsushita, Daisuke;Ohtsuka, Takao
背景/目的：研究nivolumab批准前后进展后化疗（PPC）的变化，并确定其预后影响。患者和方法：回顾性入组了146例不可切除的胃癌患者，这些患者在一线和/或二线化疗后至少出现疾病进展。结果：在146例患者中，分别有46例和23例接受了ramucirumab和nivolumab治疗。此外，95和62名患者在nivolumab批准后在一线和二线化疗后接受PPC）与A组相比，接受雷莫芦单抗疗法、nivolumab疗法和一线或二线化疗后PPC的患者比例显著更高（即，在nivolumab批准之前终止化疗）。A组预后明显差于B组。多变量分析显示，年龄、远处转移部位数量和雷莫芦单抗治疗是独立的预后因素。结论：包括PPC在内的化疗策略的改变可能有助于改善进展期胃癌患者的预后。
Background/Aim: To investigate changes in postprogression chemotherapy (PPC) before and after nivolumab approval and determine their prognostic impact. Patients and Methods: A total of 146 patients with unresectable gastric cancer who had at least progressive disease after first- and/or second-line chemotherapy were retrospectively enrolled. Results: Among the 146 patients, 46 and 23 received ramucirumab and nivolumab, respectively. Moreover, 95 and 62 patients received PPC after first- and second-line chemotherapy after nivolumab approval) had significantly higher proportions of patients receiving ramucirumab therapy, nivolumab therapy, and PPC after first- or secondline chemotherapy compared to group A (i.e., termination of chemotherapy before nivolumab approval). Group A had significantly poorer prognosis than group B. Multivariate analysis showed that age, number of distant metastatic sites, and ramucirumab therapy were independent prognostic factors. Conclusion: Changes in chemotherapeutic strategies, including PPC, might contribute to improved prognosis in patients with advanced gastric cancer.